<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Amant, Frederic</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Phase 3 Trial to Compare Postoperative Chemotherapy with Observation in Stage I or II Endometrial Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with stage I or II endometrial cancer are generally treated with surgery. Despite radical surgery, however, patients with medium- or high-risk stage I and II endometrial cancers are still at significant risk of local and distant progression. A current phase 3 study [NCT01244789] is preparing to evaluate whether survival can be improved in intermediate- and high-risk early-stage patients by offering postoperative chemotherapy instead of postoperative observation alone (standard strategy), as discussed in this article.</style></abstract><number><style face="normal" font="default" size="100%">36</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>